← All organizations
Highest phase reached
Phase 4
First clinical trial
Mar 1, 2006First marketed drug
Mar 31, 1954First NDA
Mar 31, 1954Last known activity
Feb 14, 2024
Timeline
1920s
- Jan 1, 1926
Guerbet— Founded
2020s
- Sep 21, 2022
gadopiclenol— Marketing Organization
Drugs by trial phase (21 distinct, 42 trials)
Phase 4 (15 own, 0 via acquisition)
Phase 3 (1 own, 0 via acquisition)
Phase 2 (2 own, 0 via acquisition)
Phase 1 (3 own, 0 via acquisition)
Indications
Approved for
Studied for
- Arterial Occlusive Diseases
- Arteriovenous Malformations
- Atherosclerosis
- Brain Neoplasms
- Breast Diseases
- Breast Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Central Nervous System Diseases
- Cerebral Arterial Diseases
- Coronary Artery Disease
- Coronary Disease
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Fibroadenoma
- Hemangioendothelioma
- Hemangioma
- Hemangiosarcoma
- Infertility
- Kidney Diseases
- Kidney Failure, Chronic
- Liver Diseases
- Liver Neoplasms
- Meniere Disease
- Myocardial Ischemia
- Nervous System Diseases
- Peripheral Arterial Disease
- Peripheral Vascular Diseases
- Renal Artery Obstruction
- Renal Insufficiency
Marketed drugs (5)
Recent trials (50)
- NCT06226129CollaboratorPhase 4Feb 14, 2024
- NCT06057168Study chairPhase 3Sep 7, 2023
- NCT06057168Lead sponsorPhase 3Sep 7, 2023
- NCT06010173Lead sponsorPhase 3Jul 21, 2023
- NCT05490381CollaboratorPhase 1Jan 5, 2023
- NCT05590884Lead sponsorPhase 2Sep 21, 2022
- NCT04906005Study chairPhase 1May 10, 2021
- NCT04906005Lead sponsorPhase 1May 10, 2021
- NCT04733092CollaboratorPhase 1Mar 3, 2021
- NCT04341129CollaboratorEarly Phase 1Aug 31, 2020
- NCT04373564Lead sponsorPhase 4Jul 1, 2020
- NCT03986138Lead sponsorPhase 3Jun 30, 2019
- NCT03996447Lead sponsorPhase 3Jun 3, 2019
- NCT03749252Lead sponsorPhase 2Nov 6, 2018
- NCT03604549CollaboratorPhase 4Oct 31, 2018
Details
- Founded
- Villepinte, FR Jan 1, 1926
- First NDA
- Mar 31, 1954
- Last known activity
- Feb 14, 2024
Designations held
- Priority review